Bayer has announced a major restructure of its operations in 2019 which will see the loss of 12,000 of its 118,200 positions following a number of lawsuits in the wake of its $63 billion buyout of agricultural biotech firm Monsanto.
The move “aims to strengthen its core life science businesses through a series of portfolio, efficiency and structural measures designed to enhance productivity and innovation while significantly improving competitiveness,” the company said.
